Acamprosate is not a controlled substance. It carries no DEA scheduling whatsoever, meaning it is not classified under any of the five controlled substance schedules (I through V). It requires a prescription, but it does not come with the additional restrictions, monitoring, or refill limitations that apply to controlled medications.
Why Acamprosate Has No DEA Schedule
The DEA places drugs on controlled substance schedules based on their potential for abuse, dependence, and diversion. Acamprosate has none of these risks. In clinical trials at therapeutic doses, patients showed no signs of withdrawal when they stopped taking it, and no evidence of tolerance building over time. Post-marketing surveillance data collected outside the U.S. has similarly found no evidence of abuse or dependence. The drug simply doesn’t produce the kind of rewarding or euphoric effects that lead to misuse.
This sets it apart from some other medications used in addiction treatment. Buprenorphine, for instance, is a Schedule III controlled substance, and its prescribing involves tighter oversight. Acamprosate requires none of that. There are no Risk Evaluation and Mitigation Strategy (REMS) requirements, no special provider certifications, and no caps on how many patients a prescriber can treat with it.
What Acamprosate Actually Does
Acamprosate is FDA-approved for treating alcohol use disorder. Sold under the brand name Campral, it is designed to help people who have already stopped drinking maintain their abstinence. It does not reduce cravings in the way most people imagine, and it will not prevent intoxication or withdrawal if someone drinks while taking it.
Its exact mechanism is not completely understood, but the leading explanation centers on two brain signaling systems that get thrown out of balance by chronic heavy drinking. Alcohol suppresses excitatory brain activity and enhances calming activity. Over time, the brain compensates by ramping up its excitatory signaling (driven by a chemical called glutamate) and dialing down its calming signaling (driven by GABA). When someone stops drinking, that imbalance persists, leaving the brain in an overexcited, anxious state that can last for months. Acamprosate appears to dampen the overactive glutamate system, helping restore the balance between excitation and calm. Chemically, it resembles both GABA and a related compound called taurine, which likely explains how it interacts with these pathways.
How It Is Prescribed
Because acamprosate is not a controlled substance, prescribing and refilling it works like any standard prescription medication. Your provider can call it in or send it electronically to a pharmacy without the special prescription pads or quantity limits required for controlled drugs. Refills do not require a new prescription each time, unlike Schedule II medications.
The standard regimen involves taking it three times a day. This dosing schedule is one of the more common practical complaints about the medication, since remembering three daily doses can be challenging. People with moderate kidney impairment typically take a reduced dose, and acamprosate is not used at all in people with severe kidney impairment (generally defined as very low kidney filtration rates). Kidney function is one of the main things a prescriber will check before starting treatment.
How It Compares to Other Alcohol Medications
Three medications are FDA-approved for alcohol use disorder: acamprosate, naltrexone, and disulfiram. None of the three is a controlled substance. This is worth knowing because people sometimes assume that medications used in addiction treatment carry scheduling restrictions, but for alcohol use disorder, that is not the case.
Naltrexone works differently, blocking the brain’s opioid receptors so that drinking feels less rewarding. Disulfiram takes yet another approach, causing unpleasant physical reactions (nausea, flushing, rapid heartbeat) if someone drinks alcohol while taking it. Acamprosate is the only one of the three that specifically targets the glutamate imbalance left behind by chronic drinking, making it most useful for people who have already achieved abstinence and want support staying there rather than for reducing active drinking.
All three can be prescribed by any licensed provider without special certifications or waivers, a meaningful difference from some opioid use disorder medications that historically required additional training or DEA registration.